Journal of Clinical Oncology
Articles in this Issue
Artificial intelligence-powered spatial analysis of tumor infiltrating lymphocytes and tertiary lymphoid structures in non-small cell lung cancer patients treated with immune-checkpoint inhibitors±chemotherapy.
8572 Background: This study evaluates the predictive utility of an artificial intelligence (AI)-powered whole-slide image (WSI) analyzer for assessing Tum...
Hyponatremia as a predictor of in-hospital mortality in cirrhotic and non-cirrhotic hepatocellular carcinoma patients.
e16226 Background: Hepatocellular carcinoma (HCC), the most common primary liver cancer, accounts for 75–85% of liver cancer cases. Cirrhosis, a major ris...
Long-term follow-up of the phase 2 ELM-2 study: Odronextamab for patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL).
7049 Background: Odronextamab, an investigational off-the-shelf CD20×CD3 bispecific antibody, demonstrated compelling efficacy and a generally manageable...
Disparities in place of death in patients with lung cancer.
12030 Background: Place of death (PoD) significantly impacts both patient and caregiver experiences at end-of-life in the United States (U.S.), with dispa...
A case-control study of thermosensitive embolic agents (TempSLE) and microspheres in TACE treatment for hepatocellular carcinoma combined with hepatic arterioportal fistulas.
e16324 Background: Hepatic arterioportal fistulas (APFs) are common in hepatocellular carcinoma (HCC). Moreover, correlated with poor prognosis, APFs ofte...
The efficacy and safety of trastuzumab deruxtecan (T-DXd) in HER2-positive and -low metastatic breast cancer with brain metastases (BCBM): A retrospective, multicenter, real-world study.
e13120 Background: Accumulating data demonstrate both overall and intracranial activity of Trastuzumab deruxtecan (T-DXd) in HER2 positive breast cancer b...
Assessment of quality-of-life inclusion in phase III clinical trials for advanced gastrointestinal cancers: A 2020–2024 systematic review.
e23185 Background: Metastatic and advanced gastrointestinal (GI) cancers negatively impact patients' lifespans and quality of life (QoL). As clinical tria...
A randomized, double-blind, three-arm, parallel group, phase 1 study to assess the pharmacokinetics, safety, and tolerability of PERT-IJS following a single dose of 420 mg intravenous infusion compared to the EU- and US-marketed drug product (pertuzumab; PERT) in healthy male volunteers.
e13009 Background: PERT-IJS is a proposed biosimilar to reference pertuzumab (PERT). This study assessed the pharmacokinetic (PK) equivalence, safety, tol...
Case study: Is there any impact of insurance type on disposition outcomes in cancer patients on comfort care and hospital bed availability?
e23242 Background: This retrospective study evaluates if insurance type affects disposition outcomes and demographics of cancer patients on comfort care....
Racial disparities and prognostic factors in cancer-specific survival for patients with metastatic rectal cancer.
e15674 Background: Significant advances in early diagnosis and treatment have improved cancer-specific survival rates for rectal cancer. However, these ga...
Prognostic significance of PSA>0.2 after 6-12 months treatment for metastatic hormone-sensitive prostate cancer (mHSPC) intensified by androgen-receptor pathway inhibitors (ARPI): A multinational real-world analysis of the IRONMAN registry.
5002 Background: Phase III post-hoc analyses show poor prognosis of PSA >0.2 in mHSPC treated by androgen deprivation t...
Preoperative and postoperative risk prediction models based on perirenal fat and immune infiltration for small renal tumors: A multicenter cohort study.
e16514 Background: The obesity paradox in clear cell renal cell carcinoma (ccRCC) has drawn attention, with studies suggesting perirenal fat may serve as...
A first-in-human study of MT-303, an innovative in vivo mRNA chimeric antigen receptor (CAR) therapy targeting GPC3, in adults with hepatocellular carcinoma.
TPS4218 Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality worldwide, with advanced ca...
Assessing risk factors for the development of pulmonary hypertension in patients with myeloproliferative neoplasms: A meta-analysis and meta-regression.
e18594 Background: Myeloproliferative neoplasms (MPN) are widely prevalent hematological malignancies, associated with a poor prognosis and often occur in...
Efficacy and safety of alectinib in pediatric and adult patients with ALK altered advanced solid tumors: Results from the TACKLE phase II trial, a MASTER KEY substudy (NCCH1712/MK003).
3105 Background: Alectinib is an orally administered tyrosine kinase inhibitor that targets anaplastic lymphoma kinase (ALK) and is approved in ALK-positi...
Using single-cell transcriptomics to reveal CD226 upregulation and enhancement of CD19-CAR-T function in the inhibitory CNS microenvironment of refractory CNS lymphoma.
2020 Background: Refractory CNS lymphoma (CNSL) has a poor prognosis, with 5-year survival of ~30%. We conducted a trial of axi-cel for CNSL, where we ach...
Disparities in outcomes of esophageal cancer hospitalizations: A trend analysis (2008-2021).
e16156 Background: Esophageal cancer has a poor prognosis with a 21.6% five-year relative survival and demographic variations have been reported with esop...
Neoadjuvant cemiplimab in cutaneous basal cell carcinoma of the head and neck.
TPS9606 Background: Surgical resection of locally advanced basal cell carcinoma of the head and neck (laBCCHN) is often not feasible due to tumor size and...
Impact of PD-L1 high expression on the prognosis of patients with locally advanced gastric cancer.
e16103 Background: To investigate the relationship between PD-L1 expression and survival outcomes in patients (pts) with locally advanced gastric or gastr...
Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 trial.
6024 Background: EGFR is a known oncogenic driver in HNSCC, and the leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) is associated with...
Retrospective validation of a novel multimodal AI prognostic tool integrating digital pathology and clinical data against real world data and Oncotype DX in a Swiss breast cancer cohort.
e13595 Background: Accurate risk stratification in hormone receptor positive, HER2 negative (HR+/HER2-) breast cancer (BC) is critical for guiding persona...
Association of medical debt with cancer incidence rates in the US.
11012 Background: Medical debt is a growing challenge for U.S. patients and has been associated with higher cancer mortality. However, whether medical deb...
Regional disparities in cancer biomarker knowledge and access across Canada.
e13547 Background: Clinical trials are essential to the advancement of cancer therapies, yet accrual rates remain low. Multiple challenges contribute to t...
Early predictors of treatment-free remission in chronic myeloid leukemia.
6565 Background: Tyrosine kinase inhibitors (TKIs) have significantly improved outcomes for chronic myeloid leukemia (CML), allowing most patients to achi...
A shortcut from ovarian cancer development to metastasis <i>:</i> <i>MYC/FASN/SEMA7A</i> , a promising therapeutic axis.
e17542 Background: Ovarian cancer is the leading cause of mortality among gynecologic malignancies. Trans coelomic metastasis is the most common and is re...